.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Identifying EGFR Mutations in NSCLC and Optimizing Therapy

EP. 1: Recommended Mutation Testing in Lung Cancer

November 20th 2014

EP. 2: Frontline Treatment of Advanced NSCLC

November 20th 2014

EP. 3: Frontline Afatinib in EGFR-Mutant NSCLC

November 20th 2014

EP. 4: Patient-reported Outcomes with TKIs

November 20th 2014

EP. 5: Dosing Strategies for Managing TKI-Related Side Effects

November 20th 2014

EP. 6: Treating Acquired Resistance to TKIs in NSCLC

November 20th 2014

EP. 7: Reconsideration of Gefitinib in EGFR-Mutant NSCLC

November 20th 2014

EP. 8: Team Approach to Lung Cancer Care Is Essential

November 20th 2014

EP. 9: Making EGFR-Positive NSCLC a Chronic Disease

November 20th 2014